Karin Jooss
Chief Tech/Sci/R&D Officer bij GRITSTONE BIO, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Karin Jooss is an Independent Director at Fate Therapeutics, Inc. since 2019.
She is also the Executive VP & Head of Research & Development at Gritstone bio, Inc. since 2021.
Previously, she worked as the Vice President of Research at Cell Genesys, Inc. from 2005 to 2009 and as the Head of Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016.
Dr. Jooss holds a doctorate degree from Philipps University of Marburg.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0.40% | 01-02-2024 | 395 204 ( 0.40% ) | 1 M $ | 31-03-2024 |
FATE THERAPEUTICS, INC.
0.01% | 06-06-2023 | 9 848 ( 0.01% ) | 72 284 $ | 31-03-2024 |
Actieve functies van Karin Jooss
| Bedrijven | Functie | Begin |
|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 13-04-2016 |
| FATE THERAPEUTICS, INC. | Director/Board Member | 14-03-2019 |
Eerdere bekende functies van Karin Jooss
| Bedrijven | Functie | Einde |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01-04-2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Chief Tech/Sci/R&D Officer | 01-04-2009 |
Opleiding van Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
